Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNAseq in Dbh-iCre;LSL-MYCN mouse model of neuroblasoma

ABSTRACT: The initiation of drug response in neuroblastoma was assessed using this genetically engineered mouse model. scRNAseq was employed to determine the heterogeneity of the initial transcriptional response to the common chemotherapeutic drug, cisplatin.

ORGANISM(S): Mus musculus

PROVIDER: GSE229226 | GEO | 2023/04/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression profiling of murine MYCN-driven neuroblastomas from LSL-MYCN; Dbh-iCre mice.

2014-09-01 | GSE51297 | GEO

scRNAseq in Dbh-iCre LSL-MYCN mouse model of neuroblasoma

Project description:scRNAseq in Dbh-iCre LSL-MYCN mouse model of neuroblasoma

| PRJNA953432 | ENA

Expression profiling of murine MYCN-driven neuroblastomas from LSL-MYCN; Dbh-iCre mice.

Project description:Amplification of MYCN is the most prominent genetic marker of high-stage neuroblastoma, a childhood tumor originating from the neural crest. We generated a transgenic mouse with Cre-conditional induction of MYCN in dopamine beta hydroxylase expressing cells that develops murine neuroblastomas. The expression profiles of six tumors from adrenals and two tumors from superial cervical gangliae were compared to three non-malignant adrenals from wildtype mice. These profiles of adrenals have been previously described (Molenaar et al., Nature Genetics 2012). Wild type samples are accessible at the AMC webpage: http://hgserver1.amc.nl/cgi-bin/r2/main.cgi, and accessible for registered users.

2014-09-01 | E-GEOD-51297 | biostudies-arrayexpress

Metabolic dependencies in MYCN-driven neuroblastoma

Project description:Here we sought metabolic alterations specifically associated with amplified MYCN as nodes to indirectly target the MYCN oncogene. Liquid chromatography-mass spectrometry-based proteomics identified 7 proteins consistently correlated with MYCN in proteomes from 49 neuroblastoma biopsies and 13 cell lines. Among these were phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in de novo serine synthesis. MYCN associated with two regions in the PHGDH promoter, supporting transcriptional PHGDH regulation by MYCN. Pulsed stable isotope-resolved metabolomics utilizing 13C-glucose labeling demonstrated higher de novo serine synthesis in MYCN-amplified cells compared to cells with diploid MYCN. An independence of MYCN-amplified cells from exogenous serine and glycine was demonstrated by serine and glycine starvation, which attenuated nucleotide pools and proliferation only in cells with diploid MYCN but did not diminish these endpoints in MYCN-amplified cells. Proliferation was attenuated in MYCN-amplified cells by CRISPR/Cas9-mediated PHGDH knockout or treatment with PHGDH small molecule inhibitors without affecting cell viability. PHGDH inhibitors administered as single-agent therapy to NMRI-Foxn1nu/nu mice harboring patient-derived MYCN-amplified neuroblastoma xenografts slowed tumor growth. However, combining a PHGDH inhibitor with the standard-of-care chemotherapy drug, cisplatin, revealed antagonism of chemotherapy efficacy in vivo. Emergence of chemotherapy resistance was confirmed in the genetic PHGDH knockout model in vitro. Altogether, PHDGH knockout and inhibition by small molecules consistently slows proliferation, but stops short of killing the cells, which then establish resistance to classical chemotherapy. Although PHGDH inhibition with small molecules has produced encouraging results in other preclinical cancer models, this approach must be considered with caution in patients with neuroblastoma.

2020-12-11 | PXD018300 | Pride

scRNAseq in a panel of neuroblasoma cell lines

Project description:The similarity of preclinical models to human neuroblastoma tumors was evaluated with scRNAseq. The 13 NB cell lines represent a cross section of disease risk, clinical subtypes, genomic alterations, and disease phenotypes.

2023-04-10 | GSE229224 | GEO

G Protein-coupled Receptor 91 (GPR91) Indicates Prognosis and Enhances Chemoresistance by Regulating DNA Damage Pathway and ERK Signaling Pathways in Neuroblastoma

Project description:This study first reveals that GPR91 is a potential oncogene in neuroblastoma, which is significantly correlated with poor prognosis and significantly represses the sensitivity to chemotherapeutic drugs including doxorubicin and cisplatin of NB cells. It is regulated by GPR91 though the DNA damage pathway and the ERK signaling pathway.

2022-04-02 | GSE199784 | GEO

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma (SCC)

Project description:Genomic analyses of SCC have yet to yield significant strategies against pathway activation to improve treatment. Platinum-based chemotherapy remains the mainstay of treatment for SCC of different histotypes either as a single agent or alongside other chemotherapeutic drugs or radiotherapy; however, resistance inevitably emerges, which limits the duration of treatment response. To elucidate mechanisms that mediate resistance to cisplatin, we compared drug-induced perturbations to gene expression between cisplatin-sensitive and -resistant SCC cells. Cisplatin-sensitive and -resistant SCC cells were identified through MTS assay. Gene expression profiling (Affymetrix GeneChip 1.0ST) was performed to identify putative genes and cellular pathways that may be associated with cellular response to cisplatin.

2015-08-05 | E-GEOD-66549 | biostudies-arrayexpress

MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to ROS augmenting agents

Project description:Through a small scale metabolic-modulator screening, we have identified dimethyl fumarate (DMF), a FDA approved drug for multiple sclerosis, which suppresses neuroblastoma cell growth in vitro and in vivo. Mechanistically, DMF suppresses neuroblastoma cell growth through inducing ROS and subsequently suppressing MYCN expression.

2018-04-18 | GSE98241 | GEO

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma (SCC)

2015-08-05 | GSE66549 | GEO

BTLA NTN scRNAseq

Project description:BTLA NTN scRNAseq

| PRJNA926654 | ENA